Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...
By Berkeley Lovelace Jr. The Biden administration on Friday released the next round of prescription drugs selected ...
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...
2h
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...
Sanders: I welcome the Biden administration’s announcement that Medicare will finally begin to negotiate the price of Ozempic and Wegovy.
The U.S. government targets Novo Nordisk's drugs, including Ozempic and Wegovy, for Medicare price negotiations in 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback